Berger Montague Investigates Securities Fraud Claims Against Hims & Hers Health Inc.

Strategic Insights -

Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. after the company's shares dropped significantly following the termination of its partnership with Novo Nordisk due to unauthorized marketing and sale of compounded semaglutide drugs. The investigation focuses on whether Hims & Hers made false or misleading statements to investors during the class period from April 29, 2025, through June 22, 2025. A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws.

Key Takeaways:

  • Berger Montague is investigating potential securities fraud claims against Hims & Hers Health Inc. related to the company's unauthorized marketing and sale of compounded semaglutide drugs.
  • The investigation focuses on whether Hims & Hers made false or misleading statements to investors during the class period from April 29, 2025, through June 22, 2025.
  • A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws.
  • Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit.
  • Lead plaintiffs help direct the case and advocate on behalf of other harmed investors.
  • Andrew Abramowitz and Caitlin Adorni are the contact persons for more information or to discuss investor rights.
  • Berger Montague has offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, and Chicago.

Statistics:

  • Shares of Hims & Hers dropped more than 34% after Novo Nordisk revealed it terminated its partnership.
  • The class period for the investigation is from April 29, 2025, through June 22, 2025.
  • The deadline to seek appointment as lead plaintiff is August 25, 2025.

Sources:

  • Newsfile Corp. - (July 14, 2025)
  • Berger Montague website and press release